Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 7/20 | 0.92 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.92 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.92 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.92 |
| ▸ | SRC | P12931 | 2/20 | 0.92 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.92 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.92 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.92 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.86 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.86 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.86 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.86 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.86 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.85 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.85 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.85 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.85 |
| ▸ | LDHA | P00338 | 1/20 | 0.85 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Diphosphate SCHEMBL29979301 | 1.00 | P2RY1 (0.92) | P2RY1P2RY2P2RX1P2RX3SRC | |
| Adenosine Diphosphate SCHEMBL14613190 | 1.00 | P2RY1 (0.92) | P2RY1P2RY2P2RX1P2RX3SRC | |
| Adenosine Diphosphate SCHEMBL29358868 | 1.00 | P2RY1 (0.92) | P2RY1P2RY2P2RX1P2RX3SRC | |
| Adenosine Diphosphate SCHEMBL24103 | 1.00 | P2RY1 (0.92) | P2RY1P2RY2P2RX1P2RX3SRC | |
| Adenosine Diphosphate SCHEMBL18089780 | 1.00 | P2RY1 (0.92) | P2RY1P2RY2P2RX1P2RX3SRC | |
| Adenosine Diphosphate SCHEMBL18785159 | 1.00 | P2RY1 (0.92) | P2RY1P2RY2P2RX1P2RX3SRC | |
| Adenosine Diphosphate SCHEMBL12789537 | 1.00 | P2RY1 (0.92) | P2RY1P2RY2P2RX1P2RX3SRC | |
| Adenosine Diphosphate SCHEMBL135142 | 1.00 | P2RY1 (0.92) | P2RY1P2RY2P2RX1P2RX3SRC | |
| Adenosine Diphosphate SCHEMBL14180716 | 1.00 | P2RY1 (0.92) | P2RY1P2RY2P2RX1P2RX3SRC | |
| Adenosine Diphosphate SCHEMBL29397735 | 1.00 | P2RY1 (0.92) | P2RY1P2RY2P2RX1P2RX3SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1955 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4692364-A1 | METHOD FOR PRODUCING SUBSTANCE | Mitsubishi Chemical Corporation (JP) | 2026-02-11 | — | — | EP | claimed |
| EP-4686760-A1 | SIALYLTRANSFERASES FOR THE SYNTHESIS OF SIALYLATED GLYCANS, GLYCOCONJUGATES AND GLYCOPROTEINS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-02-04 | — | — | EP | claimed |
| US-20260028656-A1 | METHOD FOR PRODUCING SUBSTANCE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2026-01-29 | — | — | US | claimed |
| US-20250320540-A1 | Point-of-Care Device for the Determination of Creatine Phosphokinase (CPK) in Biological Samples | IN VITRO DIAGNOSTIC SOLUTIONS (US) | 2025-10-16 | — | — | US | claimed |
| EP-4358979-B1 | METHOD FOR OBTAINING A PLATELET DERIVED SECRETOME AND USES THEREOF | FUNDACION PARA LA INVESTIG E INNOVACION BIOSANITARIA DEL PRINCIPADO DE ASTURIAS FINBA (ES) | 2025-10-08 | — | — | EP | claimed |
| US-20250243525-A1 | BIOCATALYTIC MANUFACTURE OF SUGAR NUCLEOTIDES | ZYMTRONIX CATALYTIC SYSTEMS, INC. (US) | 2025-07-31 | — | — | US | claimed |
| EP-4543434-A2 | COMBINATION THERAPIES WITH AN ANTI-FACTOR XI/FACTOR XIA ANTIBODY | Anthos Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | claimed |
| WO-2025019764-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | MATTERWORKS INC (US) | 2025-01-23 | — | — | WO | claimed |
| EP-4437319-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | Matterworks Inc (US) | 2024-10-02 | — | — | EP | claimed |
| EP-0542292-A2 | Method for producing 3'-phosphoadenosine 5'-phosphosulfate | UNITIKA LTD. (JP) | 1993-05-19 | — | — | EP | claimed |
| US-5094947-A | PROCESS FOR PRODUCING FRUCTOSE-1,6-DIPHOSPHATE | UNITIKA, LTD. (JP) | 1992-03-10 | — | — | US | claimed |
| US-5082564-A | Method and means for desalination of seawater and brackish water | HALFF ALBERT H (US) | 1992-01-21 | — | — | US | claimed |
| US-5049372-A | Anticancer activities in a host by increasing blood and plasma adenosine 5'-triphosphate (ATP) levels | RAPAPORT ELIEZER (US) | 1991-09-17 | — | — | US | claimed |
| EP-0385486-A1 | Process for producing fructose-1,6-diphosphate | UNITIKA LTD. (JP) | 1990-09-05 | — | — | EP | claimed |
| EP-0352477-A2 | Use of adenosine 5'-phosphat in the treatment of cancer cachexia | Rapaport, Eliezer (US) | 1990-01-31 | — | — | EP | claimed |
| US-4880918-A | Arrest and killing of tumor cells by adenosine 5-diphosphate and adenosine-5-triphosphate | RAPAPORT ELIEZER (US) | 1989-11-14 | — | — | US | claimed |
| EP-0100022-B1 | PHARMACEUTICAL COMPOSITION CONTAINING ADENOSINE DERIVATIVES FOR USE IN TREATING TUMOURS | Rapaport, Eliezer (US) | 1988-04-20 | — | — | EP | claimed |
| EP-0100022-A1 | Pharmaceutical composition containing adenosine derivatives for use in treating tumours | Rapaport, Eliezer (US) | 1984-02-08 | — | — | EP | claimed |
| US-4247633-A | Reagent for colorimetric determination of creative phosphokinase | PABST BREWING COMPANY (US) | 1981-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028656-A1 | METHOD FOR PRODUCING SUBSTANCE | NADK, NAMPT, PRPS1 | P2RY1 49/4885P2RY2 44/4885P2RX1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.